Novo Nordisk A/S Faces Class Action Securities Lawsuit

Novo Nordisk A/S, a leading diabetes care company, has been sued in a class action securities lawsuit alleging securities fraud. The lawsuit claims that Novo Nordisk provided false and misleading statements to investors, understating its growth potential and overstating the market for its GLP-1 medications. As a result, investors who suffered losses may be eligible to recover their losses under the federal securities laws. Novo Nordisk's stock price plummeted 21.83% in a single day after the company announced a lower sales and profit outlook, leaving many investors wondering if they were misled.

Key Takeaways:

• The lawsuit alleges that Novo Nordisk provided false and misleading statements to investors, understating its growth potential and overstating the market for its GLP-1 medications.
• The lawsuit claims that Novo Nordisk's statements concealed material adverse facts about the company's growth potential.
• The lawsuit alleges that Novo Nordisk's stock price declined dramatically after the company announced a lower sales and profit outlook.
• Investors who suffered losses may be eligible to recover their losses under the federal securities laws.
• Novo Nordisk attributed the decline in sales and profit outlook to "lowered growth expectations," "the persistent use of compounded GLP-1s," "slower-than-expected market expansion," and "competition."
• The lawsuit is being led by Levi & Korsinsky, LLP, a nationally-recognized securities litigation firm with a track record of winning high-stakes cases.

Statistics:

• Novo Nordisk's stock price declined 21.83% in a single day after the company announced a lower sales and profit outlook.
• The company's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025.
• Merck's GLP-1 medications, Wegovy and Ozempic, were mentioned as contributing factors to Novo Nordisk's lower sales and profit outlook.

Sources:

• Newsfile Corp. press release, August 25, 2025
• Novo Nordisk A/S (NYSE: NVO) investor relations webpage
• Levi & Korsinsky, LLP website and contact information listed in the press release.